CN202433383U - Joint inspection test paper for influenza A virus antigen and influenza B virus antigen - Google Patents

Joint inspection test paper for influenza A virus antigen and influenza B virus antigen Download PDF

Info

Publication number
CN202433383U
CN202433383U CN2011205387582U CN201120538758U CN202433383U CN 202433383 U CN202433383 U CN 202433383U CN 2011205387582 U CN2011205387582 U CN 2011205387582U CN 201120538758 U CN201120538758 U CN 201120538758U CN 202433383 U CN202433383 U CN 202433383U
Authority
CN
China
Prior art keywords
influenza
virus
antibody
detection
test paper
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2011205387582U
Other languages
Chinese (zh)
Inventor
王继华
张健
郭诗静
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Wandfo Biotechnology Co.,Ltd.
Original Assignee
WONDFO BIOTECH CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by WONDFO BIOTECH CO Ltd filed Critical WONDFO BIOTECH CO Ltd
Priority to CN2011205387582U priority Critical patent/CN202433383U/en
Application granted granted Critical
Publication of CN202433383U publication Critical patent/CN202433383U/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

The utility model discloses a joint inspection test paper for an influenza A virus antigen and an influenza B virus antigen; the test paper comprises a sample pad, a glass fiber membrane containing a colloidal gold particle marker, a nitrocellulose membrane and an absorbent paper; the nitrocellulose membrane comprises a detection region coated with an influenza A virus antibody, a detection region coated with an influenza B virus antibody, and a control region coated with a goat-anti-rabbit antibody; the colloidal gold particle marker comprises a micro-signal amplification system and a rabbit IgG antibody marked by colloidal gold; and the micro-signal amplification system is a colloidal gold particle-avidin-biotin-influenza A/B virus antibody. The biotin-avidin micro-signal amplification system is added in the double-antibody sandwich testing system, so that the signal of the target antibody is amplified, the detection sensitivity is enhanced, the false negative and detection omission caused by too weak signals are avoided, meanwhile, the influenza A and B virus antigens are synchronously inspected in a jointed inspection manner, so that the detection time, the samples and the detection cost are saved.

Description

The joint inspection test paper of a kind of influenza A virus antigen and influenza B virus antigen
Technical field
The utility model belongs to field of medical examination, relates in particular to the joint inspection test paper of a kind of influenza A virus antigen and influenza B virus antigen.
Background technology
Influenza is commonly referred to " influenza ", is the acute respiratory infectious disease that is caused by influenza virus, has very strong infectiousness, mainly through the cough and the propagation of sneezing, and general spring and outburst in winter.Be divided into A type (first type) influenza virus, Type B (B-mode) influenza virus and C type (third type) influenza virus.Influenza A virus has extremely strong variability, and B virus takes second place, and the third type virus is then highly stable, so the detection of first type virus and B virus is particularly important.
According to statistics, the annual influenza case in the whole world is 6-12 hundred million, and wherein the severe influenza is 300-500 ten thousand examples, dead 25-50 ten thousand people, and the case fatality rate of severe influenza can reach 8%-10%.At present the death toll that causes of the annual influenza of the U.S. surpasses the death toll that traffic accident and AIDS cause, and has become the No.1 formidable enemy of serious harm human health in China and developing country.China is the district occurred frequently of influenza, and influenza popular or local breaks out basically that have every year, has every year people more than 100,000,000 to suffer the puzzlement of influenza, surpasses 500,000 people to the hospitalier of hospital.
The method that present stage is detected influenza infection mainly comprises Virus culture method, RT-PCR method and colloidal gold immunity chromatography.Virus culture is the goldstandard that virus detects, but this detection method cycle is very long, generally takes 3~7 days time, and sensitivity is not high; RT-PCR realizes detecting to sample in can 4-8 hour, and sensitivity is very high with specificity, but is not suitable on the airport, the density of population such as port, railway station, hospital are big, flow of the people big, be difficult for letting the public place of the long-time gathering of crowd; Colloidal gold immunity chromatography is owing to the equipment that need not assist, and use in accumulating easily and the basic unit place that is highly suitable for easy and simple to handle, but present stage sensitivity is not high, causes omission easily, still can not distinguish the virus infections hypotype.
Chinese patent CN200910087632.5 discloses a kind of primer special and the kit and the pairing target sequence of this primer that comprise the detection H1N1virus of this primer that belongs to the detection H1N1virus in pathogen gene quick diagnosis field.The pairing target sequence of the primer special of the utility model, this kit utilize gene reverse transcription and isothermal amplification technique principle, and A (H 1 N 1) virus nucleic acid is carried out fast detecting, but the testing result naked eyes judge that electrophoresis also capable of using is analyzed.But this method length consuming time, expense is big, is unfavorable for large tracts of land popularization and civil nature.
Chinese patent CN200910085475.4 discloses the method that a kind of influenza virus rRT-PCR detects primer and probe and detects influenza virus; Comprise influenza A virus Auele Specific Primer and probe, two groups of new H1N1virus H1 Auele Specific Primers and probe, new influenza A virus Auele Specific Primer and probe etc.; 4 kinds of totally 12 Oligonucleolide primers and probe sequences disclose sample process to be checked, rRT-PCR reaction system and reaction conditions, interpretation of result simultaneously.The deficiency of this method also is owing to expensive, needs the instrument and the operating personnel of specialty need pass through professional training.So also being suitable for, this method do not popularize and civil nature.
Same; The patent No. is that the patent of CN200810022489.7 has been announced and a kind ofly detected the method for influenza and H5N1 subtype avian influenza virus, patent that application number is CN201110223913.6 by liquid-phase chip and announced that first type/influenza B virus nucleic acid double fluorescent PCR detection kit, application number are that the patent of CN201010171355.9 has been announced and reached new H1N1virus one by people's first, influenza B to manage many detecting methods and kit, application number be 201110149333.7 to have announced double fluorescent quantitative RT-PCR detection kit and application; All there is the long problem of expense height, the professional instrument of needs, sense cycle in these methods, are unfavorable for that influenza test is in family, in basic unit and more extensively promote the use of among the crowd.
Application number is the kit that the utility model patent multi-link detection reagent kit of CN200710040792 discloses a kind of multinomial joint inspection; But this kit is made up of many detector bars; Though joint inspection does not synchronously reach the maximum medical disposable material consumption that reduces, not enough environmental protection.
Application number is that CN200910040975 has announced a kind of nucleic acid nano-gold biosensor that is used to detect influenza A virus and H1N1virus, is through scribbling the nano gold mark oligonucleotide probe on the spun glass and on nitrocellulose filter, fixing two kinds of oligonucleotide probes and detect object.But because influenza has first type and B-mode branch, this utility model just can not realize the purpose that detects simultaneously, and detection time, basic need was more than half an hour.
The utility model content
The purpose of the utility model is to solve that the influenza virus testing cost that exists in the prior art is expensive, sense cycle is long, low slightly and can not detect the defective of first type and influenza B virus simultaneously with nm of gold sensitivity, and a kind of new influenza A virus antigen and the joint inspection test paper of influenza B virus antigen are provided.
For realizing above-mentioned purpose, the utility model has been taked following technical scheme:
The joint inspection test paper of a kind of influenza A virus antigen and influenza B virus antigen; Said test paper is overlapped in order to stick on the base plate by sample pad, the glass fibre membrane that contains the colloid gold particle label, nitrocellulose filter, thieving paper and constitutes; Said colloid gold particle label comprises the rabbit igg antibody of micro-signal amplification system and colloid gold label, and said micro-signal amplification system is colloid gold particle-Avidin-biotin-first type or influenza B virus antibody; Said detection zone comprise be coated with influenza A virus detection of antibodies line be coated with influenza B virus detection of antibodies line, said Quality Control district is coated with goat anti-rabbit antibody.
Preferably, the said distance that is coated with influenza A virus detection of antibodies line and is coated with between the influenza B virus detection of antibodies line is 2-5mm.More preferably, the said distance that is coated with influenza A virus detection of antibodies line and is coated with between the influenza B virus detection of antibodies line is 3.5mm.
Enlarge deficiency and the problem that can not detect two kinds of somatotypes simultaneously in order to solve signal; The utility model adopts the influenza antigen in functional color micro-sphere technology (colloid gold particle labelling technique), micro-signal amplifying technique (Avidin-biotin system and double-antibody sandwich reaction system) and the joint inspection technology for detection human secretion based on the solid-phase immunity chromatographic theory.If contain influenza A virus antigen or influenza B virus antigen in the sample, the micro-signal cascade system on glass fibre membrane is amplified signal, and first type/influenza B virus antigen is combined with the colloid gold particle label; Form compound; And be diffused on the nitrocellulose filter further chromatography, when running into the pairing antibody that the T1 line that is coated on detection zone on the nitrocellulose filter or T2 line (being respectively first type or influenza B virus antibody sandwich line) locate, compound then combines with coated antibody again; Be trapped in and encapsulate the place; When captive compound reaches some, then form macroscopic T line, contain first type or influenza B virus antibody in the interpret sample; If do not occur, the negative or content of interpret sample is lower than the LDL of test paper.Control zone (C line) is as the quality control standard of test paper, and positive and negative sample all can occur when detecting.
Compared with prior art, the utlity model has following beneficial effect:
(1) the utility model is on the basis of existing detection test paper; Added biotin-avidin micro-signal cascade amplification system; Thereby, in the process that detects first type/influenza B virus antigen, enlarged the signal of target antibody; Increase detection sensitivity, avoid occurring false cloudy perhaps omission because of signal is too weak; Simultaneously, through adjusting different preparation technology parameters, detect when being implemented on same the test strips two kinds of somatotypes.
(2) test strips of the utility model have handling safety (no radiation pollute), easy (one step of simple operations accomplishes), be fit to single/part detect (put exempt from, enzyme exempt to be not suitable for single/part or small amount of sample detect) with advantages such as (about 15 minutes the result can be arranged) fast, can realize first type/influenza B virus antigen scene and family's self check; It is high and can not realize the defective of somatotype to remedy present stage chromatography kit sensitivity, can reduce risk that crowd massing infects to greatest extent, lower the harm that disease causes in that epidemic situation is on-the-spot;
(3) test paper of the utility model can be implemented in the first type that detects simultaneously on the paper slip, B-mode two kinds of influenza viruses, has shortened sense cycle, reduces because certain somatotype of single detection and the phenomenon of omission, and has practiced thrift medical disposable material.
Description of drawings
Fig. 1 is the structural representation of joint inspection test paper of influenza A virus antigen and the influenza B virus antigen of the utility model;
Reference numeral: 1. sample pad; 2. glass fibre membrane; 3. nitrocellulose filter; 4. thieving paper; 5. base plate; 6. influenza A virus detection zone; 7. influenza B virus detection zone; 8. control zone.
Embodiment
Specify the utility model below in conjunction with accompanying drawing and specific embodiment.
The joint inspection test paper of embodiment 1 the utility model influenza A virus antigen and influenza B virus antigen
As shown in Figure 1, be the joint inspection test paper of described a kind of influenza A virus antigen of the utility model and influenza B virus antigen.The glass fibre membrane that contains the colloid gold particle label 2 that comprises sample pad 1, closely links to each other with said sample pad 1 one ends, the nitrocellulose filter 3 that closely links to each other with said glass fibre membrane 2 other ends and the thieving paper 4 that closely links to each other with the other end of said cellulose membrane 3; Said sample pad 1, glass fibre membrane 2, nitrocellulose filter 3 and thieving paper 4 all are arranged on the base plate 5; Said nitrocellulose filter 3 comprises and is coated with influenza A virus detection of antibodies line 6, is coated with influenza B virus detection of antibodies line 7 and is coated with the control zone 8 of goat anti-rabbit antibody; Said colloid gold particle label comprises the rabbit igg antibody of micro-signal amplification system and colloid gold label; Said micro-signal amplification system is colloid gold particle-Avidin-biotin-Antibody of Influenza, and wherein Antibody of Influenza is influenza A virus antibody or influenza B virus antibody.
The test paper of this embodiment, the colloid gold particle-Avidin-biotin-consumption of influenza A virus antibody complex on glass fibre membrane 2 is 71 μ g/cm 2Colloid gold particle-Avidin-biotin-the consumption of influenza B virus antibody complex on glass fibre membrane 2 is 75 μ g/cm 2The consumption of rabbit igg antibody on glass fibre membrane 2 of colloid gold label is 35 μ g/cm 2The original concentration of influenza A virus antibody is 3.00mg/ml; The original concentration of influenza B virus antibody is 3.5mg/ml; The concentration of the detection zone 6 that encapsulates nitrocellulose membrane 3 during with detection zone 7 is respectively 1.2mg/ml and 1.3mg/ml, encapsulates consumption and is respectively 0.216 μ g/mm and 0.234 μ g/mm; Consumption when goat anti-rabbit igg antibody is coated on the control zone is 0.33 μ g/mm.
The preparation method of the test paper of this embodiment is:
In the utility model, adopt the colloid gold particle mark.Wherein the particle diameter of colloid gold particle size is that (30~50nm), the adsorption mechanism of colloidal solid is to utilize its electronegative character under alkali condition to nanoscale, with the positive charge group of protein molecule, depends on electrostatic attraction to combine to form immune diagnostic reagent.The preparation process of the joint inspection test paper of influenza A virus antigen and influenza B virus antigen is following:
1. prepare first/influenza B virus antibody
Utilize conventional method with the first/influenza B antigen of reorganization or the influenza antigens immune mouse of deactivation; After the mouse of first/influenza B antigen immune and myeloma cell are merged; Differentiate with the ELISA method; The hybridoma that discriminating is come out is cultivated screening positive clone, separation and purification first/influenza B virus antibody in ascites.ELISA identifies the activity of first/influenza B virus antibody and tires that purifying is subsequent use, and the original concentration of influenza A virus antibody is 3.00mg/ml, and the original concentration of influenza B virus antibody is 3.5mg/ml.
2, preparation micro-signal amplification system
A, preparation colloid gold label Avidin (the neutral affinity prime of U.S. Thermo company): with Avidin to be marked 4 ℃ of dialysed overnight in the NaCl of 0.005mol/L pH7.0 solution in advance; To remove unnecessary salt ion; 4 ℃ of 100 centrifugal 1h of 000g removes polymkeric substance then; With pH value to 8~9 of 0.1mol/L PBS adjusting collaurum (by the conventional method preparation) liquid, by the amount that adds 15~25 μ g Avidins in the 1ml colloidal gold solution, the mark Avidin is to form the colloid gold label Avidin;
B, preparation biotin (the EZ-Link NHS-Biotin of U.S. Thermo company) are changed first/influenza B virus antibody: the first connection with biotin with the 6-aminohexose makes long-armed biotin; It is combined with first/influenza B antigen; The mass ratio of biotin and influenza A virus antibody is 1: 9, and the mass ratio of biotin and influenza B virus antibody is 1: 10.Then under the effect of carbodiimide with itself and N-hydroxy-succinamide contract with; Generate long-armed biotin N-maloyl imines ester (N-hydroxy-succinimido-6-biotinyl amido hexanoate; BCNHS), be biotinylation first/influenza B virus antibody.Remove free biotin through dialysis.
C, completion micro-signal amplification system: press the amount that adds 100 μ l biotinylation first/influenza B virus antibody in the 1ml colloid gold label Avidin solution; Biotinylation first/influenza B virus antibody that colloid gold label Avidin that step a is obtained and step b obtain directly mixes; Connect and obtain collaurum-Avidin-biotin-first/influenza B virus antibody complex; After washing, centrifugal treating, promptly get the micro-signal amplification system.
3, the rabbit igg antibody of colloid gold label
In pH6.5~7.0 scopes, rabbit igg and colloid gold particle albumen (minimum amount is 8.0 μ g/ml) mark forms colloid gold label rabbit igg antibody (albumen probe).
4, collaurum-Avidin-biotin-first/influenza B virus antibody and colloid gold label rabbit igg antibody are sprayed onto on the glass fibre membrane 2, dilution parameters (dilution parameters is the technological parameter of every how many areas of ml spray solution) is 25cm 2/ ml~35cm 2/ ml, the consumption of colloid gold particle-Avidin-biotin-influenza A virus antibody complex are 71 μ g/cm 2The consumption of colloid gold particle-Avidin-biotin-influenza B virus antibody complex is 75 μ g/cm 2The consumption of the rabbit igg antibody of colloid gold label is 35 μ g/cm 2And 20~40 ℃ of temperature, humidity 10%-30% is dry more than 12 hours, subsequent use with glass fibre membrane 2.
5, with encapsulating damping fluid (its prescription that encapsulates damping fluid is 0.01M pH7.2PBS, 5% sucrose, 1% methyl alcohol, 5% glycocoll, 0.05%NaN3) dilution first and influenza B virus antibody; Make its concentration be respectively 1.2mg/ml and 1.3mg/ml; Be respectively 0.216 μ g/mm and 0.234 μ g/mm by encapsulating consumption; With its careful respectively being sprayed onto uniformly on the nitrocellulose filter 3, wherein nitrocellulose filter 3 apertures are 5.0 μ m~12.0 μ m, place 20~40 ℃; Oven dry was handled more than 12 hours under humidity 10%~30% condition, and is subsequent use; With encapsulating damping fluid dilution goat anti-rabbit igg antibody, making its concentration is 1.5mg/ml, is 0.33 μ g/mm by encapsulating consumption; With its careful being sprayed onto uniformly on the nitrocellulose filter 3, place 20~40 ℃, oven dry is handled more than 12 hours under humidity 10%~30% condition; Envelope, subsequent use;
6, sample pad 1, glass fibre membrane 2, nitrocellulose filter 3 and thieving paper 4 are pasted on the base plate 5 in regular turn, promptly get said joint inspection test paper.
The joint inspection test paper of said influenza A virus antigen and influenza B virus antigen can directly use through packing, perhaps is installed in the kit, cooperates little dropper, serves as reagent card and uses.
Embodiment 2 utilizes the method for first in the detection paper juice among the embodiment 1/influenza B virus antigen
Present embodiment utilizes the test paper of embodiment 1 that the first in the juice sample/influenza B virus antigen is detected.
May further comprise the steps:
(1) gathers sample: use the polyester sponge swab of aseptic PP (polypropylene) bar to gather sample.
Nasal secretion acquisition method: when collecting nasal secretion; Swab is inserted in the nasal cavity the many places of secretion, rotates gently and to the inner swab that promotes of nasal cavity, until concha (from the place of being obstructed of the about 2.0cm in nostril~2.5cm); Paste nasal wall rotation swab three times, take out swab;
Throat secretion is gathered: swab is inserted from the oral cavity the throat fully, is the center with the rubescent position of throat wall, maxilla almond, and appropriateness is wiping bilateral pharyngeal tonsils and pharynx rear wall firmly, should avoid touching tongue, takes out swab.
(2) after the collected specimens; Vertical 400 μ l (about 10) the sample extraction liquid that adds inserts the swab after the sampling in the solution in the sample extraction pipe in the sample extraction pipe, rotates about 10 times near inboard wall of test tube; Make sample be dissolved in the solution as far as possible; Cotton swab head along extraction tube inwall extruding swab is stayed in the pipe liquid as far as possible, takes out and discard swab.The sample extraction liquid that adopts viral sample solution or this kit to provide after the collection of specimens is as early as possible handled.As can not handle immediately, sample should place immediately in drying, sterilization and the plastic tube of strict seal and store, can preserve 8 hours under 2 ℃~8 ℃, but-70 ℃ of long preservation.
(3) tear along the aluminium foil bag cutting part, take out strip and keep flat, draw 5 μ l samples and vertically drip in the sample application zone shown in the strip arrow glue; Because capillarity, sample will move with nitrocellulose filter 3 to the plain film 2 of spun glass along test paper, treat sample fully through plain film 2 of spun glass and nitrocellulose filter 3, and the result begins to show;
Observe display result (result displayed is invalid after 30 minutes) after (4) 15 minutes; Interpretation is also write down testing result; If a macroscopic dark line (T2 line appears in the detection zone of nitrocellulose filter 36; Be the A district), show promptly and contain a large amount of influenza A virus antigens in the sample that the human body that i.e. explanation receives the proofer is passive armor type influenza infection (influenza A virus is positive); If a macroscopic dark line (T1 line, i.e. B district) appears in detection zone 7, show promptly and contain a large amount of influenza B virus antigens in the sample that i.e. explanation receives proofer's human body to be infected (influenza B virus is positive) by influenza B virus; If T1 line and T2 line occur simultaneously, i.e. the human body that explanation receives proofer infection (A district and B district) passive armor type and influenza B virus the time; If the detection zone of nitrocellulose filter 36 a macroscopic dark line all do not occur with detection zone 7, promptly show and do not contain a large amount of influenza antigens in the sample, explain to receive the proofer not by virus infections (feminine gender); When the detection zone 6 of sample through nitrocellulose filter 3 moves to control zone 8 with detection zone 7, no matter in the sample whether first/influenza B virus antigen is arranged, all can there be a dark line (C line) control zone 8; If control zone 8 no colo(u)r streaks occur, explain that test strips is expired or operate wrong;
(5) behind the EOT, test paper, sample extraction pipe and oral cavity ST after using are handled by the biologic medical discarded object.
Measure the result: in order to represent that conveniently A represents influenza A virus antigen in following table, B represents influenza B virus antigen.
Test paper among the embodiment 1 to human influenza virus's different subtype and not the influenza A virus and the influenza B virus of homophyletic good reactivity is all arranged, result of study is seen table 1.
Table 1 pair people's first type/influenza B virus detection of antigens sensitivity result
2. the test paper among the embodiment 1 all has good reactivity to other subtype influenza viral cultures of deactivation, and result of study is seen table 2.
The testing result of table 2 pair swine flu and avian influenza virus culture
3. the accuracy of the test paper among the embodiment 1
1. with blind method synchronous detection 1928 increments of like product (" the first type influenza virus antigen detecting agent box (colloidal gold method) " of Hangzhou Genesis Biodetection & Biocontrol Ltd. and " B-mode influenza virus antigen detecting agent box (colloidal gold method) ") this (wherein containing) through 156 parts in the 2009 popular H1N1 samples confirmed; Positive coincidence rate is 95.58%; Total coincidence rate is 92.63%, and testing result is seen table 3.
Table 3 and like product comparative result
Annotate: "+/+" represent that evaluation reagent and reference reagent testing result are with positive; "+/-" represent that evaluation reagent is positive, reference reagent is negative; "-/+" represent that evaluation reagent is negative, reference reagent is positive; "-/-" represent that evaluation reagent and reference reagent are with negative.
2. with PCR relatively, detect 766 increments this (wherein containing) altogether through 156 parts in the 2009 popular H1N1 samples confirmed, positive coincidence rate is 52.47%, total coincidence rate is 73.37%, testing result is seen table 4.
Table 4 and PCR method comparative result
Annotate: "+/+" represent that evaluation reagent and reference reagent testing result are with positive; "+/-" represent that evaluation reagent is positive, reference reagent is negative; "-/+" represent that evaluation reagent is negative, reference reagent is positive; "-/-" represent that evaluation reagent and reference reagent are with negative.
3. to 156 parts of H1N1 samples through confirming, the test paper of embodiment 1 detects 104 parts of positives, and positive coincidence rate is 66.67%.
4. compare with Virus culture goldstandard method, detect 355 increments altogether originally, the test paper sensitivity of embodiment 1 is 96.80%, and total coincidence rate is 90.70%, and testing result is seen table 5.
Table 5 and Virus culture goldstandard method comparative result
Annotate: "+/+" represent that evaluation reagent and Virus culture method testing result are with positive; "+/-" represent that evaluation reagent testing result is positive, Virus culture method testing result is negative; "-/+" represent that evaluation reagent testing result is negative, Virus culture method testing result is positive; "-/-" represent that evaluation reagent and Virus culture method testing result are with negative.
5. with like product (" the first type influenza virus antigen detecting agent box (colloidal gold method) " of Hangzhou Genesis Biodetection & Biocontrol Ltd. and " B-mode influenza virus antigen detecting agent box (colloidal gold method) ") 630 parts of nose swab clinical samples of blind method synchronous detection; Positive coincidence rate is 97.59%; Total coincidence rate is 97.14%, and testing result is seen table 6.
The testing result of table 6 nose swab
Annotate: "+/+" represent that evaluation reagent and reference reagent testing result are with positive; "+/-" represent that evaluation reagent is positive, reference reagent is negative; "-/+" represent that evaluation reagent is negative, reference reagent is positive; "-/-" represent that evaluation reagent and reference reagent are with negative.
6. with like product (" the first type influenza virus antigen detecting agent box (colloidal gold method) " of Hangzhou Genesis Biodetection & Biocontrol Ltd. and " B-mode influenza virus antigen detecting agent box (colloidal gold method) ") 1268 parts of throat swab clinical samples of blind method synchronous detection; Positive coincidence rate is 94.78%; Total coincidence rate is 90.38%, and testing result is seen table 7.
The testing result of table 7 throat swab
Annotate: "+/+" represent that evaluation reagent and reference reagent testing result are with positive; "+/-" represent that evaluation reagent is positive, reference reagent is negative; "-/+" represent that evaluation reagent is negative, reference reagent is positive; "-/-" represent that evaluation reagent and reference reagent are with negative
The joint inspection test paper of embodiment 3 the utility model influenza A virus antigens and influenza B virus antigen
The joint inspection test paper structure of influenza A virus antigen among this embodiment and influenza B virus antigen is identical with the structure of embodiment 1; Different is that the colloid gold particle-Avidin-biotin-consumption of influenza A virus antibody on glass fibre membrane is 45 μ g/cm 2Colloid gold particle-Avidin-biotin-the consumption of influenza B virus antibody complex on glass fibre membrane is 50 μ g/cm 2The consumption of rabbit igg antibody on glass fibre membrane of colloid gold label is 25 μ g/cm 2The influenza A virus antibody sandwich is 0.15 μ g/mm to the consumption that encapsulates of the detection zone of nitrocellulose membrane, and the influenza B virus antibody sandwich to the consumption that encapsulates of the detection zone of nitrocellulose membrane is and 0.2 μ g/mm; Consumption when goat anti-rabbit igg antibody is coated on the control zone is 0.18 μ g/mm.
The preparation method of the joint inspection test paper among this embodiment is identical with the preparation method of the test paper of embodiment 1.
The test paper of the test paper of this embodiment and embodiment 1 and like product are seen shown in the table 8 at the comparing result aspect detection sensitivity and the specificity.
The test paper of table 8 embodiment 1,3 and like product detection sensitivity and specific comparing result
Can find out that from table 8 test paper of embodiment 1 is at the test paper that obviously is superior to embodiment 3 aspect sensitivity and the specificity, and the sensitivity of comparing with Hangzhou Creative Company like product is higher, more helps detecting of influenza virus.

Claims (3)

1. the joint inspection test paper of influenza A virus antigen and influenza B virus antigen; Said test paper is overlapped in order to stick on the base plate by sample pad, the glass fibre membrane that contains the colloid gold particle label, nitrocellulose filter, thieving paper and constitutes; It is characterized in that; Said colloid gold particle label comprises the rabbit igg antibody of micro-signal amplification system and colloid gold label, and said micro-signal amplification system is colloid gold particle-Avidin-biotin-first type or influenza B virus antibody; Said detection zone comprise be coated with influenza A virus detection of antibodies line be coated with influenza B virus detection of antibodies line, said Quality Control district is coated with goat anti-rabbit antibody.
2. the joint inspection test paper of influenza A virus antigen according to claim 1 and influenza B virus antigen; It is characterized in that the said distance that is coated with influenza A virus detection of antibodies line and is coated with between the influenza B virus detection of antibodies line is 2-5mm.
3. the joint inspection test paper of influenza A virus antigen according to claim 2 and influenza B virus antigen; It is characterized in that the said distance that is coated with influenza A virus detection of antibodies line and is coated with between the influenza B virus detection of antibodies line is 3.5mm.
CN2011205387582U 2011-12-20 2011-12-20 Joint inspection test paper for influenza A virus antigen and influenza B virus antigen Active CN202433383U (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2011205387582U CN202433383U (en) 2011-12-20 2011-12-20 Joint inspection test paper for influenza A virus antigen and influenza B virus antigen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2011205387582U CN202433383U (en) 2011-12-20 2011-12-20 Joint inspection test paper for influenza A virus antigen and influenza B virus antigen

Publications (1)

Publication Number Publication Date
CN202433383U true CN202433383U (en) 2012-09-12

Family

ID=46782822

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011205387582U Active CN202433383U (en) 2011-12-20 2011-12-20 Joint inspection test paper for influenza A virus antigen and influenza B virus antigen

Country Status (1)

Country Link
CN (1) CN202433383U (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102445537A (en) * 2011-12-20 2012-05-09 广州万孚生物技术有限公司 Combined detection test paper of influenza A virus antigen and influenza B virus antigen and preparation method thereof
CN104101706A (en) * 2014-07-28 2014-10-15 国家纳米科学中心 Colloidal gold immunochromatography test strip used for testing H1N1 influenza antigen and method for testing H1N1 influenza antigen

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102445537A (en) * 2011-12-20 2012-05-09 广州万孚生物技术有限公司 Combined detection test paper of influenza A virus antigen and influenza B virus antigen and preparation method thereof
CN104101706A (en) * 2014-07-28 2014-10-15 国家纳米科学中心 Colloidal gold immunochromatography test strip used for testing H1N1 influenza antigen and method for testing H1N1 influenza antigen
CN104101706B (en) * 2014-07-28 2016-05-18 国家纳米科学中心 A kind of method that detects the colloidal gold immuno-chromatography test paper strip of first stream antigen and detect first stream antigen

Similar Documents

Publication Publication Date Title
CN102445537A (en) Combined detection test paper of influenza A virus antigen and influenza B virus antigen and preparation method thereof
CN101943699B (en) Test strip for detecting HIV antibodies in spittle and preparation method thereof
JP6150559B2 (en) Detection method of Mycoplasma pneumonia
CN103926404B (en) B race streptococcus quantum dot immune chromatography detects reagent card and preparation method thereof
CN103645314A (en) Test strip card capable of automatically filtering sample
CN103743901A (en) Colloidal gold test strip for detecting canine parvovirus
CN111273001A (en) System for rapidly detecting new coronavirus 2019-nCoV in blood sample and preparation method thereof
CN202433383U (en) Joint inspection test paper for influenza A virus antigen and influenza B virus antigen
CN102539755A (en) Test strip for detecting influenza A virus antigen in secretion and preparation method thereof
CN204731247U (en) H7 subtype avian influenza virus colloidal gold strip
CN202075280U (en) Rapid detection kit for influenza A (H1N1) virus immunomagnetic beads
CN101614740B (en) Hepatitis A virus antigen saliva fast detection test paper strip
CN103146651B (en) Test strip capable of testing infectious bovine rhinotracheitis virus (IBRV) by monoclonal antibody mediated nano gold spot infiltration method
CN102435732A (en) Toxoplasma IgM antibody immunoblotting kit and preparation method thereof
CN102305861B (en) Reagent strip for carrying out joint detection on Toxoplasma gondii IgM (immunoglobulin M) and IgG (immunoglobulin G) antibodies and preparation method thereof
CN107589253A (en) A kind of H9 subtype avian influenza virus fluorescent chromatographic test strips and its application
CN202453358U (en) Magnetic bead immune chromatography kit for blood transfusion screening joint detection
CN204203235U (en) Nettle rash vaccine effect of inoculation Fast Evaluation kit
CN204422542U (en) Two len antibodies inspect paper slip soon
CN203299202U (en) Colloidal gold test strip for rapidly detecting Mycoplasma suis in whole blood
CN106124767A (en) Respiratory syncytial virus IgA antibody test strip and detection method thereof
CN202256346U (en) Toxoplasma immunoglobulin M (IgM) antibody western blotting kit
CN105891489A (en) Test paper for detecting HBcAb (hepatitis B core antibody) IgM (immunoglobulin m) in serum and preparation method of test paper
CN102435744A (en) Colloidal gold immunochromatography assay reagent strip for total antibodies to Toxoplasma gondii and preparation method thereof
CN209400545U (en) Rabies viruses gold-immunochromatographyreagent reagent for assay and kit

Legal Events

Date Code Title Description
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: GUANGZHOU WONDFO BIOTECH. CO., LTD.

Free format text: FORMER NAME: GUANGZHOU WONDOFO BIOMEDICAL CO., LTD.

CP01 Change in the name or title of a patent holder

Address after: 510663 Guangzhou, Luogang District Science City, litchi Road, No. 8, No.

Patentee after: Guangzhou Wandfo Biotechnology Co.,Ltd.

Address before: 510663 Guangzhou, Luogang District Science City, litchi Road, No. 8, No.

Patentee before: Wondfo Biotech Co., Ltd.